STOCK TITAN

[Form 4] Enovis Corporation Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Positive)
Form Type
4

Damien McDonald, listed as Chief Executive Officer and Director of Enovis Corporation (ENOV), purchased 6,457 shares of Enovis common stock on 09/11/2025. The reported weighted-average price per share was $30.97, with transaction prices ranging from $30.73 to $31.16. After the purchase, the reporting person beneficially owned 102,753 shares. The Form 4 was signed on behalf of Mr. McDonald by attorney-in-fact Brian P. Hanigan.

Damien McDonald, indicato come Amministratore Delegato e Direttore della Enovis Corporation (ENOV), ha acquistato 6.457 azioni ordinarie di Enovis in data 09/11/2025. Il prezzo medio ponderato per azione riportato era di 30,97 dollari, con prezzi delle transazioni compresi tra 30,73 e 31,16 dollari. A seguito dell'acquisto, la persona riportante la notifica deteneva beneficiariamente 102.753 azioni. Il Modulo 4 è stato firmato per conto del signor McDonald dall'avvocato-in-fatto Brian P. Hanigan.

Damien McDonald, listado como Director Ejecutivo y Director de Enovis Corporation (ENOV), compró 6.457 acciones comunes de Enovis el 11/09/2025. El precio medio ponderado por acción reportado fue de $30,97, con precios de transacción entre $30,73 y $31,16. Tras la compra, la persona que presenta el informe poseía beneficiosamente 102.753 acciones. El Formulario 4 fue firmado en nombre del Sr. McDonald por el apoderado Brian P. Hanigan.

Damien McDonald는 Enovis Corporation(ENOV)의 CEO 겸 이사로 등재되어 있으며 2025년 9월 11일에 Enovis 보통주 6,457주를 매수했습니다. 보고된 가중평균 매입가 per 주당 가격은 $30.97였고 거래가격은 $30.73에서 $31.16 사이였습니다. 매수 후 신고자는 102,753주를 실제로 소유하게 되었습니다. Form 4는 McDonald 씨를 대신해 법정대리인인 Brian P. Hanigan이 서명했습니다.

Damien McDonald, indiqué comme président-directeur général et administrateur de Enovis Corporation (ENOV), a acheté 6 457 actions ordinaires de Enovis le 11/09/2025. Le prix moyen pondéré par action signalé était de 30,97 $, les prix de transaction allant de 30,73 $ à 31,16 $. Après l’achat, la personne déclarant possédait bénéfiquement 102 753 actions. Le Formulaire 4 a été signé au nom de M. McDonald par l’avocat-in-fait Brian P. Hanigan.

Damien McDonald, aufgeführt als Geschäftsführer und Vorstand der Enovis Corporation (ENOV), hat am 09/11/2025 6.457 Enovis-Stammaktien gekauft. Der gemeldete gewichtete Durchschnittspreis pro Aktie betrug 30,97 $, wobei die Transaktionspreise zwischen 30,73 $ und 31,16 $ lagen. Nach dem Kauf war die meldende Person beneficially 102.753 Aktien besitzen. Das Formular 4 wurde im Namen von Herrn McDonald von seinem Bevollmächtigten Brian P. Hanigan unterschrieben.

داميان ماكلوردان، المدرج كالرئيس التنفيذي وعضو مجلس إدارة شركة إنوفيس (ENOV)، اشترى 6,457 سهماً من أسهم إنوفيس العادية في 11/09/2025. كان السعر المتوسط المرجّح للسهم المبلغ عنه 30.97 دولاراً، مع أسعار معاملات تراوحت بين 30.73 و31.16 دولاراً. بعد الشراء، امتلك مقدم الإبلاغ ملكية فاعلة قدرها 102,753 سهماً. تم توقيع النموذج 4 نيابة عن السيد ماكلوردان بواسطة المحامي-الوكيل بريان ب. هانغان.

Damien McDonald,被列为 Enovis Corporation(ENOV)的首席执行官兼董事,于2025/09/11购买了6,457股 Enovis普通股。 报告的加权平均每股价格为$30.97,交易价格区间为$30.73至$31.16。 购买后,申报人实际持有102,753股。 Form 4 由代表 McDonald 先生的代理律师 Brian P. Hanigan 签署。

Positive
  • CEO and Director purchased shares, increasing beneficial ownership to 102,753 shares
  • Transaction fully disclosed with weighted-average price $30.97 and explicit price range $30.73–$31.16
  • Purchase executed directly (non-derivative securities), indicating an outright acquisition of common stock
Negative
  • None.

Insights

TL;DR: CEO purchase signals insider confidence; increases beneficial ownership by 6,457 shares at a weighted average of $30.97.

The transaction is a direct purchase reported on Form 4, indicating the CEO and director increased his stake to 102,753 shares. Insider purchases are commonly viewed as alignment with shareholder interests because they put personal capital at risk alongside public investors. The filing includes a weighted-average price and a disclosed price range, providing transparency about execution prices. The presence of an attorney-in-fact signature is a routine administrative detail and does not affect the substance of the disclosure.

TL;DR: 6,457-share acquisition at ~$31 each modestly increases insider ownership; transaction details are fully disclosed.

The Form 4 shows a non-derivative purchase (transaction code P) executed on 09/11/2025 with a weighted-average price of $30.97 and a disclosed price range of $30.73 to $31.16. Beneficial ownership after the trade is 102,753 shares. The specificity of the price range and the reporting of the weighted-average price meet SEC disclosure expectations and allow investors to quantify the insider's commitment without further assumptions.

Damien McDonald, indicato come Amministratore Delegato e Direttore della Enovis Corporation (ENOV), ha acquistato 6.457 azioni ordinarie di Enovis in data 09/11/2025. Il prezzo medio ponderato per azione riportato era di 30,97 dollari, con prezzi delle transazioni compresi tra 30,73 e 31,16 dollari. A seguito dell'acquisto, la persona riportante la notifica deteneva beneficiariamente 102.753 azioni. Il Modulo 4 è stato firmato per conto del signor McDonald dall'avvocato-in-fatto Brian P. Hanigan.

Damien McDonald, listado como Director Ejecutivo y Director de Enovis Corporation (ENOV), compró 6.457 acciones comunes de Enovis el 11/09/2025. El precio medio ponderado por acción reportado fue de $30,97, con precios de transacción entre $30,73 y $31,16. Tras la compra, la persona que presenta el informe poseía beneficiosamente 102.753 acciones. El Formulario 4 fue firmado en nombre del Sr. McDonald por el apoderado Brian P. Hanigan.

Damien McDonald는 Enovis Corporation(ENOV)의 CEO 겸 이사로 등재되어 있으며 2025년 9월 11일에 Enovis 보통주 6,457주를 매수했습니다. 보고된 가중평균 매입가 per 주당 가격은 $30.97였고 거래가격은 $30.73에서 $31.16 사이였습니다. 매수 후 신고자는 102,753주를 실제로 소유하게 되었습니다. Form 4는 McDonald 씨를 대신해 법정대리인인 Brian P. Hanigan이 서명했습니다.

Damien McDonald, indiqué comme président-directeur général et administrateur de Enovis Corporation (ENOV), a acheté 6 457 actions ordinaires de Enovis le 11/09/2025. Le prix moyen pondéré par action signalé était de 30,97 $, les prix de transaction allant de 30,73 $ à 31,16 $. Après l’achat, la personne déclarant possédait bénéfiquement 102 753 actions. Le Formulaire 4 a été signé au nom de M. McDonald par l’avocat-in-fait Brian P. Hanigan.

Damien McDonald, aufgeführt als Geschäftsführer und Vorstand der Enovis Corporation (ENOV), hat am 09/11/2025 6.457 Enovis-Stammaktien gekauft. Der gemeldete gewichtete Durchschnittspreis pro Aktie betrug 30,97 $, wobei die Transaktionspreise zwischen 30,73 $ und 31,16 $ lagen. Nach dem Kauf war die meldende Person beneficially 102.753 Aktien besitzen. Das Formular 4 wurde im Namen von Herrn McDonald von seinem Bevollmächtigten Brian P. Hanigan unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
McDonald Damien

(Last) (First) (Middle)
C/O ENOVIS CORPORATION
2711 CENTERVILLE ROAD, SUITE 400

(Street)
WILMINGTON DE 19317

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Enovis CORP [ ENOV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock, par value $0.001 09/11/2025 P 6,457 A $30.97(1) 102,753 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $30.73 to $31.16, inclusive. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
/s/ Brian P. Hanigan, attorney-in-fact 09/11/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for ENOV and what is their role at the company?

The reporting person is Damien McDonald, identified as both a Director and the Chief Executive Officer of Enovis Corporation.

What transaction was reported on the ENOV Form 4 dated 09/11/2025?

A non-derivative purchase of 6,457 shares of Enovis common stock was reported, executed on 09/11/2025.

At what price were the ENOV shares purchased according to the filing?

The filing reports a weighted-average price of $30.97 per share, with individual transaction prices ranging from $30.73 to $31.16.

How many ENOV shares does the reporting person own after the transaction?

Following the reported purchase, the reporting person beneficially owned 102,753 shares.

Who signed the Form 4 filing for the insider transaction?

The Form 4 was signed by Brian P. Hanigan, attorney-in-fact, on behalf of the reporting person on 09/11/2025.
Enovis Corp

NYSE:ENOV

ENOV Rankings

ENOV Latest News

ENOV Latest SEC Filings

ENOV Stock Data

1.74B
56.26M
1.56%
121.27%
12.03%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
WILMINGTON